Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration ...

Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration ...

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is among the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also listed as an oversold stock [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold companies [3]

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is listed as one of the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also identified as an oversold stock with an RSI near or below 30 [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold stocks, indicating potential for recovery [3]

Core Viewpoint - Vivos Therapeutics, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $4.64 million to support its operations in the sleep-related breathing disorder market, particularly obstructive sleep apnea (OSA) [1][4]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues, particularly OSA and snoring [7]. - The company’s devices have received FDA clearance for treating OSA in adults and children aged 6 to 17, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. Market Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed, highlighting a significant market opportunity for innovative treatments [8]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for more effective solutions [8]. Financial Activity - The company exercised warrants to purchase up to 1,982,356 shares at a reduced price of $2.34 per share, originally priced between $3.83 and $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [4].

Core Viewpoint - Vivos Therapeutics, Inc. has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $4.64 million in gross proceeds for the company [1][4]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices ranging from $3.83 to $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. - The offering is expected to close on or about January 20, 2026, subject to customary closing conditions [4]. Group 2: Company Overview - Vivos Therapeutics focuses on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [7]. - The company’s devices are FDA-cleared for treating OSA in both adults and children, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. - OSA affects over 1 billion people globally, with 90% undiagnosed, highlighting a significant market opportunity for Vivos [8]. Group 3: Strategic Intent - Vivos aims to empower healthcare providers to address the complex needs of OSA patients through innovative technology, education, and collaborations with sleep healthcare providers [9]. - The company promotes its treatment approach, known as The Vivos Method, which is a nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [10].

Core Viewpoint - Vivos Therapeutics, Inc. (VVOS) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][4]. - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to assess fair value [4]. Company Performance and Investor Sentiment - The upgrade in Vivos Therapeutics' rating reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [5]. - Analysts have raised their earnings estimates for Vivos Therapeutics, with the Zacks Consensus Estimate increasing by 11.9% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Vivos Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Company Overview - Vivos Therapeutics is a revenue stage medical technology company focused on developing and commercializing innovative diagnostic and nonsurgical treatment methods for patients with breathing and sleep issues, particularly obstructive sleep apnea (OSA) [2] - OSA is estimated to affect approximately 90 million people in the U.S. and 1 billion people worldwide, highlighting a significant market opportunity for Vivos [2] Leadership and Presentation - The fireside chat features Kirk Huntsman, CEO of Vivos Therapeutics, and Brad Amman, CFO, indicating the company's commitment to engaging with stakeholders and sharing insights about its operations [3]

Vivos Therapeutics Fireside Chat Summary Company Overview - **Company**: Vivos Therapeutics (NasdaqCM: VVOS) - **Industry**: Obstructive Sleep Apnea (OSA) Treatment Key Points and Arguments Strategic Shift and Acquisition - 2025 marked a pivotal year for Vivos, highlighted by the acquisition of the Sleep Center of Nevada (SCN) in June, which represents a transformative shift in the company's business model [2][4] - The motivation behind this pivot is the recognition of the significant health crisis posed by obstructive sleep apnea, which is linked to various comorbidities such as hypertension and cardiovascular diseases [2][3] Technology and Market Opportunity - Vivos possesses a unique technology that can correct obstructive sleep apnea within a year, contrasting with the traditional CPAP machines that patients often reject [3][4] - The company aims to educate the medical community about its FDA-cleared oral appliance devices, which are the only ones approved for moderate to severe OSA, unlike over 200 other devices that are only cleared for mild to moderate cases [26][27] Financial Performance - In Q3, Vivos reported a 76% year-on-year revenue increase, approaching $7 million, largely driven by the integration of SCN [12][21] - SCN generated $2.2 million in diagnostic service revenue, while Vivos contributed $1.3 million in treatment revenue, showcasing a synergistic approach [10][11] Operational Challenges and Demand - The company experienced overwhelming demand post-acquisition, leading to a doubling of facility size and rapid hiring of doctors and staff to meet patient needs [8][9] - Currently, patients are booking appointments into March, indicating a backlog due to high demand [9][20] Cost Dynamics and Profitability - Operating expenses increased by 77% year-over-year, attributed to the SCN acquisition and the need to scale operations [31][33] - Despite high initial costs, the treatment side of the business has much higher margins (60%-70%) compared to the diagnostic side, which is expected to drive profitability as operations stabilize [33][34] Future Growth and Partnerships - Vivos is expanding its sleep center ecosystem through partnerships, such as the recent affiliation in Detroit, which allows for capital-efficient growth without large upfront costs [6][40] - The company is prioritizing growth in the Intermountain West region and is in discussions with potential partners across the U.S. [42] Debt Management and Financial Strategy - Vivos has taken on significant debt to finance the SCN acquisition but believes that the profitability of its new model will allow it to service and eventually retire this debt [48][50] - The company is optimistic about cash flow generation from new revenue streams that require minimal capital outlay, which will help in managing debt [50][52] Market Position and Competitive Landscape - Vivos positions itself as a consolidator in the sleep center treatment business, leveraging its unique technology and growing demand for alternative OSA treatments [46][47] - The company is actively engaging with the medical community to promote its solutions and address the limitations of traditional CPAP treatments [24][28] Additional Important Insights - The demographic of new patients includes a significant number of younger individuals (ages 21-35), indicating a broader market for Vivos' solutions [44] - The company is focusing on educating both patients and healthcare providers about the benefits of its technology, aiming to increase adoption rates [25][26] This summary encapsulates the key discussions and insights from the Vivos Therapeutics fireside chat, highlighting the company's strategic direction, financial performance, and market opportunities in the obstructive sleep apnea treatment space.

Core Insights - Vivos Therapeutics, Inc. is expanding its operations with the grand opening of a new sleep testing and treatment center in Auburn Hills, Michigan, as part of its national expansion strategy to address obstructive sleep apnea (OSA) [1][3] - The new center operates under a capital-efficient affiliation model, allowing Vivos to partner with existing sleep clinics rather than solely relying on acquisitions, which enhances scalability and reduces capital intensity [2][4] - Vivos aims to provide innovative diagnostic and therapeutic solutions for OSA patients, leveraging its proprietary FDA-cleared products to improve patient outcomes and generate higher revenue for affiliated practices [3][4] Company Overview - Vivos Therapeutics focuses on developing and commercializing diagnostic and treatment methods for sleep-related breathing disorders, particularly OSA, with FDA-cleared devices for both adults and children [6][8] - The company emphasizes a non-invasive and non-pharmaceutical approach to treating OSA, known as The Vivos Method, which aims to address the root causes of the disorder rather than relying on traditional treatments like CPAP [9][7] Market Context - OSA affects over 1 billion people globally, with a significant portion undiagnosed, highlighting a substantial market opportunity for Vivos to provide effective treatments [7] - The sleep testing industry has faced pricing pressures, leading to closures and consolidations, which Vivos aims to counteract by offering differentiated treatment options through strategic affiliations [4][5]